Please wait while we retrieve your external webpage

Dana-Farber Cancer Institute Analyzes Clinical Pathway Use to Reduce Unwarranted Variation

One thought on “Dana-Farber Cancer Institute Analyzes Clinical Pathway Use to Reduce Unwarranted Variation

  1. This piece is a great example of a pathway program in process. Clinical pathways are not meant to be static. Their goal is to decrease variability and improve quality, however through the learning process, must be updated based upon experience and new learning. Hence every good pathway program must be reviewed and update periodically.

Leave a Reply